Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$20.9M | -$35.7M | -$45.1M | -$40.3M | -$82.0M | -$67.9M |
| Net income | -$20.7M | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M |
| EPS (diluted) | -$10.49 | -$4.24 | -$1.72 | -$1.30 | -$1.53 | -$0.88 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$14.1M | -$36.1M | -$37.4M | -$20.6M | -$15.6M | -$54.4M |
| Capital expenditures | — | — | — | $0.00 | $0.00 | $186K |
| Free cash flow | — | — | — | -$20.6M | -$15.6M | -$54.5M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $20.5M | $46.9M | $43.6M | $93.1M | $87.2M | $35.7M |
| Total assets | $24.6M | $173M | $135M | $110M | $217M | $168M |
| Total liabilities | $3.06M | $6.04M | $6.28M | $2.87M | $5.31M | $7.27M |
| Shareholders' equity | -$25.0M | $167M | $129M | $108M | $212M | $160M |
| Retained earnings | -$28.1M | -$75.6M | -$121M | -$156M | -$230M | -$290M |
| Shares (wtd avg diluted) | 2.19M | 12.3M | 26.3M | 27.0M | 48.2M | 67.8M |
Every figure is extracted from Climb Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.